Home
About
Overview
Sharing Data
ORCID
Help
History (12)
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction?
Epigenomic exploration of disease status of EGFR-mutated non-small cell lung cancer using plasma cell-free DNA hydroxymethylomes.
#SayHerName: Should Obstetrics and Gynecology Reckon with the Legacy of JM Sims?
The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST.
Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity.
See All 12 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity.
Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. Cancer Res. 2018 10 15; 78(20):5729-5730.
View in:
PubMed
subject areas
Humans
Immunotherapy
Macrophages
Neoplasms
Paclitaxel
Toll-Like Receptor 4
authors with profiles
Marina Chiara Garassino